MESA LABORATORIES INC /CO/
Mesa Laboratories designs and manufactures life sciences tools and quality control products for regulated applications in the pharmaceutical, healthcare and medical device industries. Headquartered in Lakewood, Colorado, it has four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Its offerings include sterilization and cleaning indicators and laboratory testing; protein analysis and peptide synthesis systems; calibration instruments, renal care meters and continuous monitoring systems; and genetic analysis instruments and consumables. Customers include manufacturers, hospitals, dental offices, clinical research laboratories, contract research organizations, academic institutions and other research and healthcare organizations. Mesa makes money from product sales, primarily consumables and hardware, and services, including maintenance, calibration, testing, and equipment support. It sells through direct sales personnel and independent distributors, with manufacturing operations in the United States and Europe.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MLAB in the last 30 days.
See all $MLAB insider activity →Jefferies reiterated its Buy rating for Mesa Laboratories and increased its price target to $150 from $125, suggesting a 9.6% upside from the Nov 10 close of $136.91, according to the firm.
Mesa Laboratories reported Q2 2027 organic growth of 2.6% and a 21.1% increase in Adjusted EBITDA. The company guided FY27 Adjusted EBITDA growth to 5%-8%, citing cost reductions and capital discipline. Challenges include SDC delivery and Clinical Genomics restructuring.
Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.
Over the past 7 days, AlphAI's AI scored 12 news stories mentioning MLAB (MESA LABORATORIES INC /CO/). Coverage has skewed bullish: 4 bullish, 7 neutral, and 1 bearish.
Recent MLAB coverage spans earnings, corporate actions and financial news.
Jefferies reiterated its Buy rating for Mesa Laboratories and increased its price target to $150 from $125, suggesting a 9.6% upside from the Nov 10 close of $136.91, according to the firm.
Earnings beat and upbeat guidance may lift the stock, but execution risks in delivery and genomics could temper upside.
New earnings and guidance release for Mesa Labs.
Positive earnings beat and first full‑year guidance suggest upside potential
The announcement sets the timing for the earnings release, allowing traders to position ahead of the market close.
AlphAI scores every news story that mentions MLAB with an AI model for sentiment and relevance, and aggregates insider trades from MESA LABORATORIES INC /CO/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jefferies reiterated its Buy rating for Mesa Laboratories and increased its price target to $150 from $125, suggesting a 9.6% upside from the Nov 10 close of $136.91, according to the firm.
Mesa Laboratories reported Q2 2027 organic growth of 2.6% and a 21.1% increase in Adjusted EBITDA. The company guided FY27 Adjusted EBITDA growth to 5%-8%, citing cost reductions and capital discipline. Challenges include SDC delivery and Clinical Genomics restructuring.
Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.
MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality
Mesa Laboratories (MLAB) will release its 2Q27 financial results after market close on Nov. 9, 2026, followed by an earnings call at 4:30 p.m. ET. The company designs and manufactures quality control solutions for pharmaceutical, healthcare, and medical device industries. A replay will be available for 45 days.
Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.
Mesa Laboratories (MLAB) plans to cut 40 jobs, or 6% of its workforce, primarily in its Clinical Genomics division, to save $9.3M annually. The company will reinvest $4.3M into growth initiatives, including business development and commercial resources in Asia. MLAB pre-market price: $128.07.
MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in
Mesa Laboratories (MLAB) declared a quarterly dividend of $0.16 per share, payable Dec 15, 2026 to shareholders of record on Nov 30, 2026. The company's dividend policy remains unchanged.
MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2026 MESA LABORATORIES, INC. (Exact name of regist
